Successful use of lanadelumab in a patient with hereditary angioedema with normal C1 inhibitor and negative genetic testing

We report an approximately 80% reduction in angioedema attacks with lanadelumab, a mAb targeting plasma kallikrein, in a case of hereditary angioedema with normal C1 inhibitor levels. This finding supports a central pathophysiologic role for kallikrein in hereditary angioedema with normal C1 levels...

Descripción completa

Detalles Bibliográficos
Autores principales: Adatia, Adil, Ritchie, Bruce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509950/
https://www.ncbi.nlm.nih.gov/pubmed/37780787
http://dx.doi.org/10.1016/j.jacig.2023.100087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509950/
https://www.ncbi.nlm.nih.gov/pubmed/37780787
http://dx.doi.org/10.1016/j.jacig.2023.100087

Ejemplares similares